Protegrin-1 and Analogues Against Acinetobacter baumannii: A Narrative Review
Abstract
A. baumannii is recognised as an important etiologic agent for hospital infections and increases the risk of postoperative complications, worsening mortality and prolonging hospitalisation. Protegrin-1 (PG-1) is one of the most promising antimicrobial peptides (AMPs) in the literature, since its antimicrobial action covers a wide range of Gram-positive and Gram-negative bacteria, including A. baumannii. PG-1 represents a valid new therapeutic option for the treatment of A. baumannii multi-drug resistant infections, showing synergic activity with traditional antibiotics, such as colistin. However, its clinical use in humans still requires studies, especially considering the haemolytic risk. For this reason, the use of PG-1 analogues, such as PLP-3, HV2, CDP-1, and IB367, seems to be the most promising way for the clinical use of this class of AMPs.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.